Here’s a breakdown of the key partnerships and collaborations mentioned in the text, along with the type of revenue they generate for Harbour BioMed:
* AstraZeneca & Bristol Myers Squibb: Platform-based research collaboration – generates recurring revenue.
* Otsuka: Licensing collaboration – generates recurring revenue (from out-licensing).
* Windward Bio: Licensing collaboration – generates recurring revenue (from out-licensing).
* Pfizer: Research and technology license collaboration – generates revenue from technology license and potentially milestone payments (from existing collaborations).
* Nona Biosciences: Technology license and platform-based service – generates revenue from technology license and platform-based service.
The overall theme is a shift towards recurring revenue streams through strategic partnerships,rather than one-off deals. This is highlighted as a key factor in Harbour BioMed’s anticipated profitability.
Worth a look